Conditional relative survival in Waldenstrom's macroglobulinaemia: a population-based study in The Netherlands

被引：5

作者：

Amaador, Karima ^{[1
,2
]}

Kersten, Marie Jose ^{[1
,2
]}

Visser, Otto ^{[3
]}

Posthuma, Eduardus F. M. ^{[4
,5
]}

Minnema, Monique C. ^{[6
]}

Vos, Josephine M., I ^{[1
,2
]}

Dinmohamed, Avinash G. ^{[1
,2
,7
,8
,9
]}

机构：

[1] Univ Amsterdam, Canc Ctr Amsterdam, Dept Hematol, Amsterdam UMC, Amsterdam, Netherlands

[2] LYMMCARE Lymphoma & Myeloma Ctr Amsterdam, Amsterdam, Netherlands

[3] Netherlands Comprehens Canc Org IKNL, Dept Registrat, Utrecht, Netherlands

[4] Reinier Graaf Gasthuis, Dept Internal Med, Delft, Netherlands

[5] Leiden Univ, Dept Hematol, Med Ctr, Leiden, Netherlands

[6] Univ Utrecht, Univ Med Ctr Utrecht, Dept Hematol, Utrecht, Netherlands

[7] Netherlands Comprehens Canc Org IKNL, Dept Res & Dev, Utrecht, Netherlands

[8] Univ Med Ctr Rotterdam, Dept Publ Hlth, Erasmus MC, Rotterdam, Netherlands

[9] Vrije Univ Amsterdam, Canc Ctr Amsterdam, Dept Hematol, Amsterdam UMC, Amsterdam, Netherlands

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2022年 / 196卷 / 05期

关键词：

lymphoplasmacytic lymphoma; Waldenstrom's macroglobulinaemia; conditional relative survival; population-based; RITUXIMAB; EPIDEMIOLOGY; SURVEILLANCE; PATTERNS; TRENDS;

D O I：

10.1111/bjh.17926

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Contemporary diagnosed WM patients, compared to the general population, continue to experience excess mortality regardless of having survived up to 15 years post-diagnosis. This gradual increase in excess mortality might result from the incurable nature of this disease characterized by multiple relapses throughout the disease course with limited efficacious treatment options in the released/refractory setting.

引用

页码：1205 / 1208

页数：4

共 19 条

[1] Hybrid analysis for up-to-date long-term survival rates in cancer registries with delayed recording of incident cases [J].

Brenner, H ;

Rachet, B .

EUROPEAN JOURNAL OF CANCER, 2004, 40 (16) :2494-2501

[2] Survival trends in Waldenstrom macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database [J].

Castillo, Jorge J. ;

Olszewski, Adam J. ;

Cronin, Angel M. ;

Hunter, Zachary R. ;

Treon, Steven P. .

BLOOD, 2014, 123 (25) :3999-4000

[3] Interpreting trends in cancer patient survival [J].

Dickman, P. W. ;

Adami, H. -O. .

JOURNAL OF INTERNAL MEDICINE, 2006, 260 (02) :103-117

[4] Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstrom's Macroglobulinemia [J].

Dimopoulos, M. A. ;

Tedeschi, A. ;

Trotman, J. ;

Garcia-Sanz, R. ;

Macdonald, D. ;

Leblond, V. ;

Mahe, B. ;

Herbaux, C. ;

Tam, C. ;

Orsucci, L. ;

Palomba, M. L. ;

Matous, J. V. ;

Shustik, C. ;

Kastritis, E. ;

Treon, S. P. ;

Li, J. ;

Salman, Z. ;

Graef, T. ;

Buske, C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (25) :2399-2410

[5] Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide [J].

Dimopoulos, Meletios Athanasios ;

Anagnostopoulos, Athanasios ;

Kyrtsonis, Marie-Christine ;

Zervas, Konstantinos ;

Tsatalas, Constantinos ;

Kokkinis, Garyfallia ;

Repoussis, Panagiotis ;

Symeonidis, Argyris ;

Delimpasi, Souzana ;

Katodritou, Eirini ;

Vervessou, Elina ;

Michali, Evridiki ;

Pouli, Anastasia ;

Gika, Dimitra ;

Vassou, Amalia ;

Terpos, Evangelos ;

Anagnostopoulos, Nikolaos ;

Economopoulos, Theophanis ;

Pangalis, Gerasimos .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (22) :3344-3349

[6]

EDERER FRED, 1961, NATL CANCER INST MONOGR, V6, P101

[7] Waldenstrom macroglobulinemia treatment algorithm 2018 [J].

Gertz, Morie A. .

BLOOD CANCER JOURNAL, 2018, 8

[8]

Groves FD, 1998, CANCER-AM CANCER SOC, V82, P1078

[9] Clinical Relevance of Conditional Survival of Cancer Patients in Europe: Age-Specific Analyses of 13 Cancers [J].

Janssen-Heijnen, Maryska L. G. ;

Gondos, Adam ;

Bray, Freddie ;

Hakulinen, Timo ;

Brewster, David H. ;

Brenner, Hermann ;

Coebergh, Jan-Willem W. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15) :2520-2528

[10] Incidence, prevalence, mortality, and causes of death in Waldenstrom macroglobulinemia: a nationwide, population-based cohort study [J].

Jeong, Seri ;

Kong, Seom Gim ;

Kim, Da Jung ;

Lee, Sangjin ;

Lee, Ho Sup .

BMC CANCER, 2020, 20 (01)

← 1 2 →